SparingVision

Our CMO Kali Stasi will be participating in the RBC Capital Markets Virtual Ophthalmology Conference! She will be highlighting SparingVision’s recent progress across our gene-agnostic #gene therapy programs, SPVN06 and SPVN20. #GenomicMedicine

We are pleased to share that on March 19 our CEO @BoisselStephane will be participating in a roundtable discussion in the European Deeptech Week, organized by Bpifrance. If you’re attending and would like to connect, please DM us 🤝 #EuropeanDeeptechWeek #Innovation

Our Director Analytical Sciences, Fabien Dorange, Chief Regulatory & Quality Officer, Marie Uguen and Regulatory Affairs Senior Manager, Pauline Jacquety will be in London for @Terrapinn's Advanced Therapies Congress. Don't miss Fabien’s presentation on March 17. Details below👇

📣 March is #SaveYourVision Month in the US, an initiative dedicated to promoting the significance of regular eye check-ups and adopting habits that ensure optimal #eyehealth. 👁️ 👉 Learn more here: aoa.org/educate-your-c…

🌍#RareDiseaseDay2026! We are standing with 300 million people living with rare diseases. By pioneering gene therapies for ocular diseases, we strive to bring hope to those who need it most!

🧬Meet Pierre Axel Vinot, our Senior Director, CMC, who shares his experience at the crossroads of product development, manufacturing, and patient delivery. 👉Learn more here: sparingvision.com/blog/

🚀 Today, Pierre-Axel Vinot, our Senior Director, CMC, will be presenting at the 4th Viral Vector Process Development and Manufacturing Summit in Boston. If you are attending and would like to connect, feel free to reach out 🤝 #GeneTherapy #Biotechnology #Ophthalmology

At The 1st Japan IRD Innovation Summit in Tokyo, our CEO Stéphane Boissel represented SparingVision at this inaugural event dedicated to innovation in inherited retinal diseases. Great to connect with key stakeholders across research, to advance the development of gene therapies.

Our CEO, Stéphane Boissel, recently joined Blouse & Blazer – Episode #2: “Health start-ups: why does fundraising remain an obstacle course?” 🎧 Watch the full episode: @blouse_et_blazer" target="_blank" rel="nofollow noopener">youtube.com/@blouse_et_bla…

February shines a light on Age-Related Macular Degeneration (#AMD) and #LowVisionAwareness Month! 👁️ AMD impacts millions of people worldwide and there is an urgent need for more treatments! To learn more: preventblindness.org/amd-age-relate… #GenomicMedicines #Ophthalmology #GeneTherapy

🌍Today is the International Day of Women and Girls in Science! 🤝 At SparingVision, we are proud to work alongside women whose passion and curiosity advance our research every day. #STEM #GenomicMedicines #Ophthalmology #GeneTherapy

Our CEO Stephane Boissel is presenting at the 1st Japan IRD Innovation Summit: Advancing Vision Through Innovation! We are looking forward to discussing how we can advance the therapeutic landscape for inherited #retinal diseases. #Conference #Ophthalmology

📣We have completed dosing in our Phase I/II PRODYGY clinical trial, evaluating SPVN06, our first AAV-based gene therapy designed to preserve vision in patients with retinitis pigmentosa! Learn more: sparingvision.com/sparingvision-… #GenomicMedicines #Ophthalmology #GeneTherapy

Theres lots to look forward to across the industry and gene therapies in 2026, great to see that SparingVision has been featured in @Citeline's Scrip Asks! Read our CEO, Stephane Boissel, prediction for 2026 here: insights.citeline.com/scrip/scrip-as…

Proud to share that our CSO & CTO Mehdi Gasmi will be presenting at #Phacilitate Advanced Therapies Week on Feb 12 in San Diego. Attending the event? Let’s connect and discuss. Looking forward to it. #GenomicMedicines #Ophthalmology #GeneTherapy

Meet Pauline Jacquety, our Regulatory Affairs Senior Manager, who shares her experience as part of a team dedicated to developing and implementing regulatory strategies across the SparingVision pipeline. 🌟 Learn more here: sparingvision.com/blog/ #GenomicMedicines

💡 Fundraising is key in healthcare & biotech, where innovation requires long-term investment and expertise. Access to capital accelerates research and delivers treatments. Our CEO Stéphane Boissel took part in a dedicated episode on healthcare fundraising. 📅 Out February 12.

🌟Feeling energized after #JPM2026, where engaging conversations offered a great opportunity to share our perspective on gene therapy as a key innovation for blinding diseases amid growing interest in ocular gene therapies. Image credits: Pharmaphorum and Fierce Biotech

📣 #ICYMI – Here’s a look at where the SparingVision management team will be heading in the first half of 2026. #GenomicMedicines #Ophthalmology #GeneTherapy

🚀Kicking off 2026! Our CEO Stephane Boissel and CFO Anjeza Gjino will be at @jpmorgan Healthcare Conference in San Francisco. Attending? Let's connect to discuss our gene-agnostic therapy programs SPVN06 and SPVN20. 🤝info@sparingvision.com. #JPM2026 #GeneTherapy